অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; valsartan, quantity: 80 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; iron oxide yellow; colloidal anhydrous silica; crospovidone; purified talc; magnesium stearate; hypromellose; macrogol 8000; iron oxide red; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

lydia co., ltd. - menthol (unii: l7t10eip3a) (menthol - unii:l7t10eip3a), peppermint oil (unii: av092ku4jh) (peppermint - unii:v95r5kmy2b), pine needle oil (pinus mugo) (unii: 6kf1rln1ci) (pine needle oil (pinus mugo) - unii:6kf1rln1ci) - co cool is an essence oil that is the main ingredient of the herb extract of nature. if you put it in your nose when you feel stuffy, your nose feels cool and your head clear. apply it on the inside of the nose and under the nose as often as necessary, and gently rub the nose.

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

hospira, inc. - deferoxamine mesylate (unii: v9tko7eo6k) (deferoxamine - unii:j06y7mxw4d) - deferoxamine mesylate 500 mg - deferoxamine mesylate for injection, usp is indicated for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias. acute iron intoxication deferoxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron intoxication, which may include the following: induction of emesis with syrup of ipecac; gastric lavage; suction and maintenance of a clear airway; control of shock with intravenous fluids, blood, oxygen, and vasopressors; and correction of acidosis. chronic iron overload deferoxamine mesylate can promote iron excretion in patients with secondary iron overload from multiple transfusions (as may occur in the treatment of some chronic anemias, including thalassemia). long-term therapy with deferoxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis. iron mobilization with deferoxamine mesylate is relatively poor in patients under the age of 3 years with relativ

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

remedyrepack inc. - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin 2 mg - doxazosin mesylate tablets are indicated for the treatment of the signs and symptoms of bph. doxazosin mesylate tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood press

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - eprosartan mesylate (unii: 8n2l1nx8s3) (eprosartan - unii:2kh13z0s0y) - eprosartan 600 mg - eprosartan mesylate tablets are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensives such as diuretics and calcium channel blockers. eprosartan mesylate tablets are contraindicated in patients who are hypersensitive to this product or any of its components. do not co-administer aliskiren with eprosartan in patients with diabetes (see precautions: drug interactions).

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

padagis us llc - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 2.5 mg - bromocriptine mesylate tablets are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . bromocriptine mesylate tablets treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of bromocriptine mesylate tablets therapy may be used to reduce the tumor mass prior to surgery. bromocriptine mesylate tablets therapy is indicated in the treatment of acromegaly. bromocriptine mesylate tablets therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. since the effects of external pituitary radiation may not become

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

kv pharmaceuticals - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - tablet - 1 mg - a. benign prostatic hyperplasia (bph) doxazosin mesylate tablets are indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with bph: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). doxazosin mesylate tablets may be used in all bph patients whether hypertensive or normotensive. in patients with hypertension and bph, both conditions were effectively treated with doxazosin mesylate tablet monotherapy. doxazosin mesylate tablets provides rapid improvement in symptoms and urinary flow rate in 66-71% of patients. sustained improvements with doxazosin mesylate tablets were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. b. hypertension doxazosin mesylate tablets are also indicated for the treatment of hypertension. doxazosin mesylate tablets may be

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 2.5 mg - bromocriptine mesylate is indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. bromocriptine treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of bromocriptine therapy may be used to reduce the tumor mass prior to surgery. bromocriptine therapy is indicated in the treatment of acromegaly. bromocriptine therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately half of patients treated, although not usually to normal levels. since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with bromocriptine offers p

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

bryant ranch prepack - benztropine mesylate (unii: wmj8tl7510) (benztropine - unii:1nhl2j4x8k) - benztropine mesylate 1 mg - benztropine mesylate tablets, usp are indicated for use as an adjunct in the therapy of all forms of parkinsonism. useful also in the control of extrapyramidal disorders (except tardive dyskinesia - see precautions ) due to neuroleptic drugs (e.g., phenothiazines). hypersensitivity to benztropine mesylate tablets or to any component of the tablets. because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients. because of the atropine-like side effects, benztropine mesylate should be used with caution in pediatric patients over three years of age (see contraindications ).

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

alvogen, inc. - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) - rasagiline 0.5 mg - rasagiline mesylate tablets are indicated for the treatment of parkinson’s disease (pd). rasagiline is contraindicated for use with meperidine, tramadol, methadone, propoxyphene and mao inhibitors (maois), including other selective mao-b inhibitors, because of risk of serotonin syndrome [see warnings and precautions (5.2)]. at least 14 days should elapse between discontinuation of rasagiline and initiation of treatment with these medications. rasagiline is contraindicated for use with st. john’s wort and with cyclobenzaprine. rasagiline is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. pregnancy category c there are no adequate and well-controlled studies of rasagiline in pregnant women. rasagiline should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in a combined mating/fertility and embryo-fetal development study in pregnant rats, no effect on embryo-fetal development was observed at oral doses